195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. (December 2022) - Csiki, I.; Glenn, J.; Boccia, R.; Chen, C.; Gordon, M.; Misleh, J.; Powderly, J.; Wainberg, Z.A.; Spira, A.; Klumpp, K.